AZR · XBRL financial data
Adial Pharmaceuticals financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AZR's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 5,853 | 8,396 | 4,177 | 1,267 | 3,229 | 2,620 |
| General and administrative | 5,075 | 9,345 | 9,140 | 5,621 | 5,055 | 5,180 |
| Total operating expenses | 10,928 | 19,289 | 13,317 | 6,888 | 8,284 | 7,799 |
| Other operating income (expense) | — | — | — | — | 163 | — |
| Operating income (loss) | (10,928) | (19,289) | (13,317) | (6,888) | (8,284) | (7,799) |
| Interest income | 32 | 7 | 63 | 70 | 179 | 150 |
| Other income (expense) | — | — | — | 10 | (75) | 165 |
| Income tax expense (benefit) | — | (94) | (1) | — | — | — |
| Net income (loss) | (10,893) | (19,423) | (12,731) | (5,123) | (13,197) | (7,977) |
| Earnings per share, basic USD per share | — | (1.04) | (0.51) | (3.60) | (2.72) | (11.93) |
| Earnings per share, diluted USD per share | — | (1.04) | (0.51) | (3.60) | (2.72) | (11.93) |
| Weighted average shares, basic thousands of shares | — | 18,589 | 25,038 | — | 194 | 669 |
| Weighted average shares, diluted thousands of shares | — | 18,589 | 25,038 | 1,425 | 4,851 | 669 |
- † Share count changed about 1/7 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (AZR's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4,401 | 6,062 | 4,002 | 2,827 | 3,751 | 5,881 |
| Prepaid and other current assets | 502 | 390 | 349 | 372 | 308 | 300 |
| Total current assets | 5,136 | 6,462 | 4,780 | 3,199 | 4,059 | 6,181 |
| Property and equipment, net | — | 58 | 50 | — | — | — |
| Right-of-use asset | — | 246 | 194 | — | — | — |
| Goodwill | — | 249 | 249 | — | — | — |
| Total assets | 5,491 | 7,475 | 5,733 | 4,737 | 5,044 | 6,673 |
| Accounts payable | 649 | 286 | 394 | 103 | 250 | 655 |
| Accrued liabilities | 857 | 2,377 | 1,155 | 478 | 677 | 742 |
| Total current liabilities | 1,505 | 2,722 | 1,791 | 653 | 976 | 1,397 |
| Lease liability, non-current | — | 207 | 151 | — | — | — |
| Total liabilities | 1,505 | 3,967 | 2,456 | 653 | 976 | 1,397 |
| Accumulated deficit | (31,520) | (50,943) | (63,675) | (68,798) | (81,995) | (89,972) |
| Total stockholders' equity | 3,986 | 3,508 | 3,276 | 4,084 | 4,068 | 5,276 |
| Total liabilities and equity | 5,491 | 7,475 | 5,733 | 4,737 | 5,044 | 6,673 |
| Common shares outstanding (cover page) thousands of shares | 17,270 | 23,719 | 28,517 | 4,055 | 6,575 | 1,428 |
- † Share count changed about 1/7 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (AZR's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (10,893) | (19,423) | (12,731) | (5,123) | (13,197) | (7,977) |
| Stock-based compensation | 2,014 | 4,240 | 3,374 | 1,746 | 797 | 676 |
| Net cash from operating activities | (7,633) | (11,949) | (11,186) | (6,807) | (6,922) | (6,493) |
| Purchases of property and equipment | — | 65 | — | — | — | — |
| Net cash from investing activities | (350) | (34) | — | 1,500 | — | 150 |
| Proceeds from issuing common stock | 5,157 | 11,750 | 9,124 | 750 | 4,021 | 3,659 |
| Proceeds from issuing equity | — | — | — | — | 4,000 | 8,500 |
| Share repurchases | — | — | — | 2 | — | — |
| Net cash from financing activities | 5,607 | 13,645 | 9,126 | 4,132 | 7,846 | 8,473 |
- † Share count changed about 1/7 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Adial Pharmaceuticals | 28,712 | not reported | (6,363)* | 2.6M | 4.5 quarters | 10-Q/AJun 30, 2026 |
| AIM ImmunoTech | 9,900 | 26 | (4,590)* | 30.4M | 2.2 quarters | 10-QJun 30, 2026 |
| Vyome Holdings | 7,888 | 27 | (904)* | 7.0M | 8.7 quarters | 10-QJun 30, 2026 |
| Biomerica | 2,733 | 1,265 | (802) | 4.6M | 3.4 quarters | 10-QAug 31, 2026 |
| Protagenic Therapeutics, Inc.\new | 566 | not reported | (944) | 1.8M | 0.6 quarters | 10-QJun 30, 2026 |
| PharmaCyte Biotech | 17,739 | 0 | (781) | 10.7M | 22.8 quarters | 10-QJul 31, 2026 |
| Natural Alternatives International | 7,388 | not reported | (1,066)* | 22.1M | 6.9 quarters | 10-KJun 30, 2026 |
| LFTD Partners | 1,504 | 8,705 | (555)* | 14.8M | 2.7 quarters | 10-QJun 30, 2026 |
| CV Sciences | 266 | 2,985 | 20* | 225.8M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.